Disease landscape
Lymphoma
A moderate to high level of restrictions in diagnosis and access to lymphoma treatment has been identified in the Visegrád (V4) countries as measured in the GAP score. Results vary from country to country and the difference between the highest and the lowest score is 29 points. The main reason for limited V4 performance is the lack of reimbursement or the high reimbursement restrictions for most drugs included in analysis.
Cross-Country
General GAP for Lymphoma
Compliance with guidelines
Positive recommendations for 9 lymphoma drugs were found in the clinical practice guidelines. Althoug 5 to 8 of these are available to lymphoma patients in V4 countries and the mean guidelines compliance excess 70% in th V4 region, it should be noted that the guidelines for lymphoma are relatively outdated (only 9 out of 29 drugs registered in 2010-2023 are mentioned in the guidelines).
From registration to reimbursement
Population burden
DALY* - Rate per 100k
*disability adjusted life-years
Target population
selected drugs
Drug access
Number of patients treated (2022)
Drug access
Population treated (%) - selected drugs*
*percentage of the population potentially eligible for treatment with selected drugs: Adcetris SACLC / CTCL / HL, Opdivo HL, Imbruvica MCL.
Main issues
- The average time to reimbursement for lymphoma drugs in the V4 countries is 3.5 years. The difference between the shortest and the longest mean time to reimbursement among the states is 0.9 years.
- The proportion of patients in the target population treated with analysed selected novel drugs in 2022 is substantial in the V4 countries and is estimated to be about 50% in Poland and Hungary in, almost 80% in Czechia and over 95% in Slovakia.
- Disability adjusted life-years (DALY) burden in the V4 countries is about 10-15% lower than the EU average. As in the EU as a whole, the stabilization of burden was observed in the V4 countries in 2005-2019.
Project
We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).